Tag: BARDA
Vaxxas secures $2M grant from BARDA to develop needle-free mRNA vaccines
Vaxxas, a clinical-stage biotechnology company specializing in high-density microarray patch (HD-MAP) vaccine delivery, has been awarded a $2 million (AUD 3.2 million) grant as a Concept Stage winner in the United States Biomedical Advanced Research and Development Authority’s (BARDA) $50 million Patch Forward Prize.Â
SAB Biotherapeutics awarded $57.5 to manufacture its therapeutic candidate for COVID-19
Clinical stage biopharma company SAB Biotherapeutics has been awarded $57.5 million from BARDA and the US Department of Defence for the manufacturing of SAB-185,...
Featured Article
Driving the future of smart energy: GridBeyond and ABB unveil new white paper on battery storage innovation
As industries adopt cleaner, more intelligent energy solutions, the ability to manage, store, and trade energy efficiently is increasingly vital to sustaining a competitive edge.
